```html

Primary Liver Cancer – Comprehensive Medical Guide

Overview

Primary liver cancer (PLC) is a malignant tumor that originates in the liver cells (hepatocytes) or the bile‑duct cells (cholangiocytes). The two most common subtypes are:

• Hepatocellular carcinoma (HCC) – accounts for about 75‑85 % of PLC cases.
• Intra‑hepatic cholangiocarcinoma (iCCA) – makes up most of the remaining cases.

The disease is distinct from metastatic liver cancer, which spreads to the liver from cancers elsewhere (e.g., colon, breast).

Who is Affected?

PLC most frequently occurs in adults over 50, but it can develop at any age. Men are about twice as likely as women to develop HCC.<sup>[1][2]</sup>

Prevalence & Burden

• Globally, > 900,000 new cases of liver cancer are diagnosed each year, making it the sixth most common cancer and the third leading cause of cancer‑related death.<sup>[3]</sup>
• In the United States, the American Cancer Society estimates ~ 42,000 new cases (HCC ≈ 37,000) and ~ 30,000 deaths in 2024.<sup>[4]</sup>
• Incidence is highest in East Asia and sub‑Saharan Africa, reflecting regional differences in hepatitis B and C infections.<sup>[5]</sup>

Symptoms

Early PLC often has no noticeable signs. When symptoms appear, they may be vague and overlap with other liver diseases.

• Abdominal pain or fullness – usually in the right upper quadrant.
• Unexplained weight loss – despite normal eating habits.
• Loss of appetite or feeling quickly full.
• Fatigue or weakness – common but nonspecific.
• Jaundice – yellowing of the skin and eyes caused by buildup of bilirubin.
• Itchy skin (pruritus) – due to bile salts accumulating under the skin.
• Swelling of the abdomen (ascites) – fluid buildup from liver dysfunction.
• Swelling in the legs (edema) – often seen with advanced disease.
• Dark urine and pale stools – result of impaired bile excretion.
• Fever – may indicate tumor necrosis or infection.
• Enlarged liver (hepatomegaly) – sometimes palpable on physical exam.

Causes and Risk Factors

Primary liver cancer arises when liver cells acquire genetic mutations that trigger uncontrolled growth. Several chronic conditions increase the likelihood of these mutations.

Major Causes

• Chronic hepatitis B virus (HBV) infection – DNA integration and ongoing inflammation raise HCC risk; 50 % of global HCC cases are HBV‑related.<sup>[6]</sup>
• Chronic hepatitis C virus (HCV) infection – leads to cirrhosis, a strong precursor for HCC.<sup>[7]</sup>
• Cirrhosis of any cause – scarring disrupts normal cell turnover; 80‑90 % of HCCs arise in cirrhotic livers.
• Alcohol‑related liver disease – heavy, long‑term drinking (> 30 g/day for men, > 20 g/day for women) accelerates cirrhosis.
• Non‑alcoholic fatty liver disease (NAFLD) / non‑alcoholic steatohepatitis (NASH) – increasingly common; projected to become the leading cause of HCC in Western countries.<sup>[8]</sup>
• Aflatoxin exposure – produced by Aspergillus molds on poorly stored grains; synergistic with HBV.
• Genetic disorders – such as hemochromatosis, alpha‑1 antitrypsin deficiency, and Wilson disease.
• Congenital biliary diseases – e.g., primary sclerosing cholangitis (PSC) raise iCCA risk.

Additional Risk Factors

• Male sex (≈ 2:1 male‑to‑female ratio for HCC).
• Age > 50 years.
• Family history of liver cancer or chronic hepatitis.
• Obesity (BMI ≥ 30 kg/m²) and type 2 diabetes – linked to NAFLD/NASH.
• Smoking – increases HCC risk 1.5‑fold.
• Exposure to certain chemicals (vinyl chloride, thorotrast, anabolic steroids).

Diagnosis

Because early disease may be silent, imaging and laboratory tests are essential when risk factors exist.

Initial Evaluation

• History & physical exam – focusing on risk factors, liver‑related symptoms, and signs of chronic liver disease.
• Blood tests:
  • Complete blood count (CBC) and liver panel (ALT, AST, alkaline phosphatase, bilirubin).
  • Serum alpha‑fetoprotein (AFP) – elevated in ~ 60‑70 % of HCC patients; useful for monitoring.
  • HBV/HCV serology – to identify viral etiology.
  • Coagulation profile (INR) – assesses liver synthetic function.

Imaging Studies

1. Ultrasound (US) – first‑line screening tool for at‑risk patients (e.g., cirrhotic). Sensitivity ≈ 60‑80 % for lesions > 1 cm.
2. Contrast‑enhanced CT (computed tomography) or MRI with liver‑specific contrast (e.g., gadoxetate disodium) – provide detailed anatomy, vascular involvement, and help apply the LI-RADS classification for HCC diagnosis.
3. Contrast‑enhanced ultrasound (CEUS) – useful when CT/MRI contraindicated.

Definitive Diagnosis

• Biopsy – percutaneous, laparoscopic, or trans‑jugular. Indicated when imaging is inconclusive or for iCCA. Risks include bleeding and tumor seeding.
• Staging – Barcelona Clinic Liver Cancer (BCLC) system integrates tumor stage, liver function (Child‑Pugh), and performance status to guide treatment.

Treatment Options

Treatment is personalized based on tumor stage, liver reserve, and patient health.

Curative Intent

• Surgical resection – removal of the tumor with a margin of healthy tissue; suitable for single lesions with preserved liver function (Child‑Pugh A‑B).
• Liver transplantation – indicated for patients meeting Milan criteria (single lesion ≤ 5 cm or up to 3 lesions ≤ 3 cm each) and decompensated cirrhosc. Offers best long‑term survival.
• Ablative therapies – Radiofrequency ablation (RFA) or microwave ablation (MWA) for tumors ≤ 3 cm when surgery is not feasible.

Locoregional (Non‑Curative) Therapies

• Transarterial chemoembolization (TACE) – delivers chemotherapy directly to the tumor’s arterial supply and blocks blood flow; standard for intermediate‑stage HCC.
• Transarterial radioembolization (TARE/Y‑90) – uses radioactive microspheres; useful for patients with portal vein thrombosis.
• External beam radiation therapy (EBRT) – stereotactic body radiotherapy (SBRT) can control small lesions.

Systemic Therapies

Reserved for advanced disease or after locoregional failure.

• Immunotherapy – atezolizumab + bevacizumab (anti‑PD‑L1 + anti‑VEGF) is first‑line per 2022 FDA approval.<sup>[9]</sup>
• Tyrosine‑kinase inhibitors (TKIs) – sorafenib, lenvatinib, regorafenib, cabozantinib.
• Monoclonal antibodies – ramucirumab for patients with AFP ≥ 400 ng/mL.

Supportive & Lifestyle Measures

• Management of underlying liver disease (antiviral therapy for HBV/HCV, alcohol cessation, weight loss for NAFLD).
• Nutritional support – high‑protein, moderate‑calorie diet; consider vitamin D and B‑complex supplementation.
• Vaccination against hepatitis A and B (if not immune).
• Pain control, diuretics for ascites, and lactulose for hepatic encephalopathy.

Living with Primary Liver Cancer

Daily Management

• Medication adherence – keep a pill organizer, set reminders, and discuss side‑effects with your oncology team.
• Regular monitoring – scheduled imaging (usually every 3‑6 months) and AFP checks.
• Nutrition – aim for 1.2‑1.5 g protein/kg/day; avoid raw or undercooked shellfish (risk of infection) and limit salt to ≤ 2 g/day to control ascites.
• Physical activity – gentle walking or yoga 150 min/week, adjusted for fatigue and overall fitness.
• Alcohol & tobacco – abstain completely; both impair liver regeneration and increase recurrence risk.
• Psychosocial support – counseling, support groups, or spiritual care can reduce anxiety and depression, which affect outcomes.
• Advance care planning – discuss goals of care, do‑not‑resuscitate (DNR) orders, and hospice options early.

Follow‑up Care

Survivorship clinics often include:

• Liver function tests every 3 months.
• Imaging (US/CT/MRI) to detect recurrence.
• Screening for secondary cancers (e.g., colonoscopy).
• Bone health assessment if on long‑term TKIs.

Prevention

Because many risk factors are modifiable, primary prevention can markedly lower PLC incidence.

• Vaccinate against hepatitis B – three‑dose series reduces HCC risk by up to 80 %.<sup>[10]</sup>
• Screen and treat chronic hepatitis C – direct‑acting antivirals achieve cure rates > 95 % and lower HCC risk.
• Limit alcohol intake – ≤ 1 drink/day for women and ≤ 2 drinks/day for men; consider total abstinence if cirrhosis already present.
• Maintain a healthy weight – BMI < 25 kg/m²; weight loss of 5‑10 % improves NAFLD/NASH.
• Control diabetes and hyperlipidemia – metformin and statins may have protective liver effects.
• Avoid aflatoxin exposure – store grains and nuts in dry conditions, discard moldy foods.
• Occupational safety – use protective equipment when handling vinyl chloride, thorium dioxide, or other hepatotoxic chemicals.

Complications

If left untreated or if disease progresses, several serious complications can develop:

• Portal hypertension – leading to variceal bleeding, splenomegaly, and worsening ascites.
• Liver failure – coagulopathy, encephalopathy, and jaundice requiring transplant or palliative care.
• Metastasis – spreads to lungs, bones, or lymph nodes, worsening prognosis.
• Spontaneous bacterial peritonitis (SBP) – infection of ascitic fluid; high mortality if not promptly treated.
• Cachexia – severe weight loss and muscle wasting, reducing tolerance to therapy.
• Renal dysfunction (hepatorenal syndrome) – often precipitated by diuretics or infections.

When to Seek Emergency Care

References

1. American Cancer Society. What Is Liver Cancer? 2024.
2. World Health Organization. Global Hepatocellular Carcinoma Statistics. 2023.
3. Ferlay J, et al. GLOBOCAN 2022: Cancer Incidence and Mortality Worldwide.
4. American Cancer Society. 2024 Cancer Statistics.
5. International Agency for Research on Cancer. Liver Cancer Fact Sheet. 2023.
6. Shepard CW, et al. Hepatitis B and Hepatocellular Carcinoma. NEJM. 2022.
7. Thomas DL. Hepatitis C Virus Infection and Liver Cancer. Lancet Gastroenterology. 2023.
8. Younossi Z, et al. Global Epidemiology of NAFLD and NASH. Hepatology. 2023.
9. Finn RS, et al. Atezolizumab plus Bevacizumab in Unresectable HCC. NEJM. 2020; updated 2022.
10. World Health Organization. Hepatitis B vaccine efficacy. 2022.

```